A share price of G1 Therapeutics Inc [GTHX] is currently trading at $2.40, up 4.35%. An important factor to consider is whether the stock is rising or falling in short-term value. The GTHX shares have gain 6.19% over the last week, with a monthly amount drifted -41.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference. In a post published today on Yahoo Finance, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual Health Care Conference on Wednesday March 6, 2024 at 9:10 AM EST.
From an analyst’s perspective:
G1 Therapeutics Inc [NASDAQ: GTHX] stock has seen the most recent analyst activity on January 30, 2023, when JP Morgan upgraded its rating to a Neutral and also boosted its price target to $10 from $7. Previously, Needham reaffirmed its Buy rating on January 03, 2023, and dropped its price target to $31. On November 04, 2021, downgrade downgraded it’s rating to Underweight and revised its price target to $19 on the stock. JP Morgan downgraded its rating to a Neutral and reduced its price target to $20 on September 30, 2021. Raymond James downgraded its rating to Outperform for this stock on November 17, 2020. In a note dated June 26, 2020, ROTH Capital initiated an Buy rating and provided a target price of $55 on this stock.
G1 Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.08 and $5.00. G1 Therapeutics Inc [NASDAQ: GTHX] shares were valued at $2.40 at the most recent close of the market.
Analyzing the GTHX fundamentals
Trailing Twelve Months sales for G1 Therapeutics Inc [NASDAQ:GTHX] were 77.89M which represents -47.83% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.28 points at the first support level, and at 2.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.50, and for the 2nd resistance point, it is at 2.61.
G1 Therapeutics Inc [GTHX] reported earnings per share of -$0.35 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.33/share, meaning a difference of -$0.02 and a surprise factor of -6.10%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.14 per share as compared to estimates of -$0.22 per share, a difference of $0.36 representing a surprise of 163.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for G1 Therapeutics Inc [NASDAQ:GTHX] is 3.75. On the other hand, the Quick Ratio is 3.35, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 1.60, the price to book ratio is 2.89.
Transactions by insiders
Recent insider trading involved Malik Rajesh, Chief Medical Officer, that happened on Feb 12 when 28600.0 shares were sold. Chief Operating Officer, MURDOCK TERRY L completed a deal on Jan 04 to sell 721.0 shares. Meanwhile, Chief Business Officer Avagliano Mark sold 721.0 shares on Jan 04.
